Recursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Caitong International Asset Management Co. Ltd

Caitong International Asset Management Co. Ltd increased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 97.2% during the second quarter, HoldingsChannel.com reports. The fund owned 9,019 shares of the company’s stock after buying an additional 4,446 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Recursion Pharmaceuticals were worth $46,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the business. Clear Creek Financial Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 9.8% in the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock valued at $113,000 after acquiring an additional 1,907 shares during the period. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after acquiring an additional 2,026 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Recursion Pharmaceuticals by 16.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock valued at $78,000 after acquiring an additional 2,219 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Recursion Pharmaceuticals by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,864 shares of the company’s stock valued at $163,000 after acquiring an additional 2,587 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 0.5% in the 1st quarter. Rafferty Asset Management LLC now owns 598,420 shares of the company’s stock valued at $3,166,000 after acquiring an additional 2,948 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on RXRX. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Saturday. Finally, Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $7.25.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $6.04 on Friday. The firm has a market capitalization of $2.62 billion, a P/E ratio of -3.39 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company’s fifty day moving average is $5.18 and its two-hundred day moving average is $5.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $19.10 million for the quarter, compared to analysts’ expectations of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity

In other news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider owned 668,197 shares of the company’s stock, valued at $3,688,447.44. The trade was a 5.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 8.43% of the stock is owned by company insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.